Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue

Go back to Supernus Announces Third Quarter 2018 Financial Results and Record Quarterly Revenue

Supernus Pharma (SUPN) Tops Q3 EPS by 11c; Lowers FY Revenue Outlook

November 6, 2018 4:22 PM EST

Supernus Pharma (NASDAQ: SUPN) reported Q3 EPS of $0.52, $0.11 better than the analyst estimate of $0.41. Revenue for the quarter came in at $103 million versus the consensus estimate of $100.61 million.

GUIDANCE:

Supernus Pharma sees FY2018 revenue of $388-395 million, versus prior... More